Back to drug safety directory
Alpha-1 adrenergic blocker (BPH)Reviewed May 16, 2026

Tamsulosin (Flomax) and Ketamine Therapy | Tovani Health

Flomax (Tamsulosin)Alpha-1 adrenergic blocker (BPH)

Verdict at Tovani Health

Compatible; orthostatic hypotension is the thing we monitor.

Tamsulosin and ketamine are compatible. Tamsulosin can cause orthostatic hypotension, especially during the first weeks of therapy. After a ketamine session the recovery period is the highest-risk window for a postural drop.

If you take Flomax regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.

How Flomax interacts with ketamine

Tamsulosin selectively blocks alpha-1A receptors in the prostate and bladder neck. It also affects vascular alpha-1 to some degree, producing orthostasis particularly early in therapy.

What we do at intake

Disclose dose and how long you have been on it. Stand up slowly after the session and stay seated for several minutes.

Bottom line

Tamsulosin and ketamine are compatible. Tamsulosin can cause orthostatic hypotension, especially during the first weeks of therapy. After a ketamine session the recovery period is the highest-risk window for a postural drop.

Frequently Asked Questions

Should I hold tamsulosin on session day?

Usually no. We just plan the recovery period to minimize postural drops.

Ready to find out if at-home ketamine fits your situation?

We’ll note that you’re on Flomax (Tamsulosin) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.

FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.

Sources

The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.

  1. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535

    Comprehensive clinical pharmacokinetics/pharmacodynamics review of ketamine including CYP-mediated drug interactions (CYP3A4, CYP2B6).

Clinically reviewed

Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.

This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.